# Twenty five years of Haemovigilance in Ireland

Dr Kieran Morris

**NHO Conference** 

25 March 2025

## Krever Commission Report (Canadian Blood Services)

- The report described a public health disaster in Canada in the 1970s and 1980s
- The report detailed the events leading to the tainted blood crisis
- The report estimated that 85% of hepatitis C infections from blood transfusions between 1986 and 1990 could have been prevented
- The report concluded that the Canadian government failed to take precautionary measures to protect the blood supply
- The report found cost cutting attempts, cover ups and political interference
- The report found the negligent importation of blood from high risk American donors

### Penrose Inquiry (Scottish Blood Service)

#### Recommendation

The Inquiry recommends: That the Scottish Government takes all reasonable steps to offer a HCV test to everyone in Scotland who had a blood transfusion before September 1991 and who has not been tested for HCV

Several hundred findings (the following are selected)

- A patient needs to be able to access their records with ease
- Any failure of record keeping is likely to result in some loss of trust in the system
- There is no place for gratuitous comments in records
- Complacency is the enemy of safety
- Patient safety should have been the paramount guiding principle
- A search for certainty can be, and in this case was, the enemy of achieving progress

- Risks to public health need to be addressed with speed, consistency, and an objective look, at such evidence as there is without making unjustified assumptions
- What aids the process is a clear structure for decision making.
   Instead of effective decision making here, there was 'decision paralysis.'
- Cost, though a relevant factor, should not be the starting point.
   Patient safety should be.

Sadly, these principles were honoured more in the breech than in the observance

Over 100 recommendations (the following are selected)

- Change the culture, such that safety is embedded as a first principle, and is regarded as an essential measure of the quality of care
- A more rational approach to regulation and safety management, resolving the problems created by the current systems for trying to deliver safer care which are fragmented, overlapping, confusing and poorly understood

#### Harm and risk of harm go unaddressed because:

- Patients and service users are not listened to
- Data is not collected
- Information/intelligence/data is held in the wrong place and/or not shared with the appropriate bodies
- The extent of a risk is not identified because bodies are not pooling their intelligence/data
- Trends that can be only be spotted by taking a bird's eye view are not identified
- A joined up response is required but none is forthcoming as a result of remit apathy ('not my responsibility') and/or lack of accountability for joint working

### Regulatory aspects of blood transfusion

- Guiding principles and law
- EU Blood Directive 2002/98/EC
- Inspection/accreditation/licensing
- Enforcement and threat surveillance
- Professional organisations within the blood transfusion professional community
- The precautionary principle

## The Role of Haemovigilance in Transfusion Safety

- Confidentiality of submitted data
- Broad participation, supported by education
- Use of standardized definitions and terminology
- Nonpunitive evaluation of data
- Reporting of rates of occurrences
- Sufficient detail to make effective recommendations for improved practices
- Focus on improved safety and outcomes
- Simple and efficient operations
- Sustainable organization

### Medicolegal aspects of transfusion practice

- Ethical principles/regulatory framework/quality guidelines/duty of care/consent to transfusion
- EU Blood Safety Directive 2002/98 standards related to blood collection testing, processing, and storing
- EU Blood Safety Directive 2004/33 technical requirements
- EU Blood Safety Directive 2005/61 and 2005/62 traceability, reporting adverse reactions and events, and specifications for quality systems

## Dipping into the Archives (NHO annual reports)

Annual report 2000

Haemovigilance has been defined as

"A set of surveillance procedures, from the collection of blood and its components to the follow up of recipients, to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence"

#### The remit of the NHO is to:

- Receive, collate and follow up reports of adverse reactions/events to transfusion of blood components/products
- Advise on the follow up action necessary
- Report adverse reactions to the Irish Medicines Board (IMB) according to an agreed procedure
- Provide ongoing support to hospital based Transfusion Surveillance Officers (TSOs) and as appropriate to medical, nursing and technical staff

- Advise on improvements in safe transfusion practice based on the data supplied by hospitals
- Support the development of clinical guidelines for hospitals
- Support the audit function of hospitals
- Promote the development of fully traceable transfusion records
- Report to National Blood Users Group (NBUG) an a periodic basis with a view to developing national transfusion practice

Definition of adverse event/reaction

Adverse event: an undesirable experience occurring following administration of a blood component/product

Adverse reaction: a reaction which is harmful and unintended and which occurs following a transfusion of therapeutic volume of a blood component/product


#### Reporting forms

- Initial report form
- Incorrect blood component/blood product transfused
- Acute haemolytic or other severe acute transfusion reaction
- Delayed haemolytic transfusion reaction
- Transfusion related acute lung injury
- Severe acute anaphylaxis/anaphylactoid reactions
- Transfusion related circulatory overload
- Post transfusion purpura
- Transfusion associated graft versus host disease
- Unusual transfusion reactions

Table 1: Number of units issued by IBTS January - December 2000


| Component           | Total Issues |
|---------------------|--------------|
| Red Cells           | 124,291      |
| Platelets           | 41,207       |
| Fresh Frozen Plasma | 24,811       |
| Cryoprecipitate     | 1,848        |
| Whole Blood         | 506          |
| Combined total      | 192,663      |

#### Graph 1 NHO Incidents by Category



There were no reports received in the categories of:

- ◆ Post Transfusion Purpura, (PTP)
- ◆ Transfusion Related Acute Lung Injury (TRALI)
- ◆ Transfusion Associated Graft versus Host Disease (TAGvHD).



- Two patients required ongoing cardiac support and four patients died later of their underlying condition
- One of the patients given SD plasma to correct an abnormal INR developed TACO and subsequently died. This was a severely ill patient with underlying liver disease but the transfusion was considered unnecessary as the patient was not bleeding. The death was considered possibly related to the transfusion

### Annual report 2010/2011

During 2010, 451 reports were received - an increase of 30% (n=137) compared to the 314 reports received in 2009.

Table 5: Reports Received by the NHO 2009-2010 (n=765)

| Donowto                          | 2009 |     | 2010 |     |
|----------------------------------|------|-----|------|-----|
| Reports                          | n    | %   | n    | %   |
| Accepted reports                 | 267  | 85  | 391  | 87  |
| Reports not progressed           | 46   | 15  | 56   | 12  |
| Duplicate reports received       | 1    | 0   | 4    | 1   |
| Total number of reports received | 314  | 100 | 451  | 100 |

### Annual report 2010/2011


Table 8: Mandatory and Non-Mandatory Reports by Hospital Category (n=71\*)

| Category | Components issued (p.a). | No of<br>Reporting<br>Establishments | Near<br>Miss | SAE | SAR | Not<br>accepted | Total | Range |
|----------|--------------------------|--------------------------------------|--------------|-----|-----|-----------------|-------|-------|
| Α        | 0-1000                   | 37                                   | 5            | 26  | 15  | 10              | 56    | 0-11  |
| В        | 1000 -3000               | 18                                   | 6            | 69  | 43  | 29              | 147   | 1-26  |
| C        | 3000-6000                | 8                                    | 9            | 17  | 23  | 7               | 56    | 2-21  |
| D        | > 6000                   | 8                                    | 15           | 49  | 70  | 12              | 146   | 13-33 |

<sup>(\*</sup> Reports from two supply centres and duplicate reports were not included).

This represents a haemovigilance participation rate of 73% (n=52).

## Annual report 2010/2011



## Annual report 2010/2011 (key points – selected)

- Decision making in an emergency is very difficult and retrospective review can appear harsh however this patient did receive unnecessary transfusions
- As noted in earlier sections of this report there is little evidence to support the 'two person check'
- Transfusion should only take place if there are sufficient competent staff available to monitor the patient and the patient can be readily observed throughout the transfusion
- Testing an eluate is an important part of investigating a haemolytic transfusion reaction and may be the only way of identifying any and all of the antibodies present

## Annual report 2010/2011 (key points – selected)

- All patients receiving transfusion should have regular clinical review and assessment of their needs
- Every clinician who signs a transfusion prescription should be satisfied that the reason for every transfusion is known, evidence based and documented in the case notes. Patients with a low body mass index (BMI) will have a smaller blood volume and will require a smaller blood transfusion to achieve the same increment in haemoglobin and are at risk of TACO
- Hospital blood banks are expected to provide a quality based transfusion service underpinned by procedures and staff training. Such procedures must be put in place. Failure to provide these is considered system and not human error

## Annual report 2010/2011 (key points – selected)

- The availability of instructions and multiple documents can only lead to error. Pre transfusion instructions should be in one document and not dispensed as over compatibility report forms and prescription documents.
- As a minimum blood cultures and investigations for haemolysis should be taken on patients suffering an FHTR to exclude red cell incompatibility or bacterial contamination. A recheck should be taken to confirm the component was intended for that patient.
- Careful attention to fluid balance is essential and must be documented

#### SERIOUS Adverse Events 2019 to 2020

National Haemovigilance Office

Caroline Casey

## Components issued in 2019 and 2020

|  | RCC     | Platelets | Other<br>(Granulocyte<br>s) |
|--|---------|-----------|-----------------------------|
| Total Number of components issued 2019 | 122,582 | 21,237    | 163                         |
| Total Number of components issued 2020 | 113,766 | 21,049    | 92                          |

Table 1: The number of components issued in 2019 and 2020

#### What happened 2019?

#### Types of SAEs received in 2019 (n=87)




Figure 2: Types of SAEs received by NHO in 2019

- Other (n=22)
- Inappropriate transfusion (n=15)
- Tx of an incorrectly labelled unit (n=14)
- Failure to give an irradiated component (n=9)
- Incorrect component/product transfused (n=8)
- Tx of other ag incompatible RCC (n=7)
- Tx of incorrectly stored component (n=4)
- Incorrect ABO group transfused (n=3)
- Failure to give CMV neg and irradiated component (n=2)
- Incorrect RhD group transfused (n=1)

#### What happened 2020?

#### Types of SAEs received in 2020 (n=67)




Figure 3: The number and type of SAEs received at the NHO in 2020

- Inappropriate transfusion (n=21)
- Other (n=14)
- Incorrect component/product transfused (n=7)
- Tx of incorrectly stored component (n=6)
- Tx of other ag incompatible RCC (n=5)
- Failure to give an irradiated component (n=4)
- Tx of an incorrectly labelled unit (n=3)???
- Incorrect RhD group transfused (n=3)
- Blood or blood product given to wrong patient (n=1)
- Failure to give CMV neg and irradiated component (n=1)
- Tx of expired component (n=1)
- Failure to give CMV neg component (n=1)

## Wrong Blood in Tube (WBIT) Reports accepted 2019 – (n = 46)

Reports accepted 2020 - (n = 71)

|  | No. of reports 2019<br>(n = 46) | No. of reports 2020<br>(n =71) |
|--|---------------------------------|--------------------------------|
| Sample taken from intended patient but labelled with another patient's details | 36                              | 61                             |
| Sample taken from wrong patient but labelled with intended patient's details   | 10                              | 10                             |

Table 6: Classification and number of WBIT reports accepted by the NHO in 2019 and 2020

### What happened in 2019 and 2020?

| Patient Identification errors reported to NHO | 2019 (n = 47) | 2020 (n=77) |
|---|---------------|-------------|
| Detail on sample not transcribed from ID band | 4             | 4           |
| Patient not correctly ID at phlebotomy        | 19            | 21          |
| Patient not correctly ID at admission         | 4             | 4           |
| Sample not labelled by person taking sample   | 4             | 15          |
| Sample remotely labelled                      | 9             | 21          |
| Other   | 6             | 10          |
| Unknown                                       |               | 2           |
| Pre-labelling                                 | 1             |             |

## WBIT and electronic identification systems (EIS) 2020

- EIS in use in 24 out of 30 sites that reported WBIT events to the NHO in 2020.
- 92.2% of reported events were from sites which stated that an electronic system was in use at the time of the WBIT event.
- 26% of reported events an electronic ID system was not used during the sampling procedure.
- Of the remaining WBIT reported 34 used EBTS, 15 used MNCMS and it was unknown if an electronic sampling system was used in two incidences.

#### What can we do?

Address environmental factors?

Stop scanning bands from charts??



Address issues with printers?

Get phlebotomists to take samples?

## Key Recommendations from current WBIT data

#### Things to consider:

Removing wristbands from charts

Employing phlebotomists for out of hours sampling

Address issues with printers

## Key Recommendations from 2019 and 2020

We need to address the human factor principle

We need more detail in our descriptions

We need to learn from excellent practices

We need to ensure our systems are robust and we are resilient

'To make no mistakes is not in the power of man; but from their errors and mistakes the wise and good learn wisdom for the future.'

#### **Plutarch**






#### NHO Serious Adverse Reactions 2019-2020


Joanne Scanlon



## Total number of reports received in the NHO 1999 -2020 (n= 7682)



# SAE's/SAR's V's Components issued (0.002%)





- Components issued 2019-2020: 278.889
- SAE's/SAR'S reported: 695





## Summary of Data 2019-2020







## **Transfusion reactions**

| Acute Transfusion<br>Reactions (n=148) | Immunological Haemolysis due to ABO incompatibility | 0  |
|--|---|----|
|  | Febrile Non Haemolytic Transfusion Reaction         | 72 |
|  | Anaphylaxis/Hypersensitivity                        | 61 |
|  | Hypotensive Transfusion Reactions                   | 3  |
|  | Unclassified Reaction                               | 12 |




## Febrile Reactions (n=72) Components

#### **Findings**

- 78 Reports received
- 72 Reports accepted
- 10 Reports Mandatory

#### **Demographics**

- 1-4 yr: 2
- 12-17 yr: 1
- 18-30 yr: 5
- 31-50 yr: 16
- 51-70 yr: 20
- 70+:28



#### **Clinical Outcome**


- Complete Recovery: 64
- Minor Sequelae: 7
- Death: 1(unrelated to transfusion)



### **Februle Reactions**

#### **Investigations**

- Bact screening of unit: 46
- Bact screening of pt: 62
- Bact screening of both pt and unit: 41





## Anaphylaxis/hypersensitivity (n=61)

- Number of reports received: n =68
- No. of reports accepted: 61

#### Clinical Outcome:

- Deaths: 0
- Complete Recovery: 54
- Minor Sequelae: 6
- Serious Sequleae: 1

#### **Demographic Data**

**†** 30 **†** 31

Adults: 58

Less than 4 Years: 3

#### **Components:**

Red Cells n= 18

Apheresis Platelets n= 29

Pooled Platelets n=8

Plasma n= 3

Multiple Components n=3



## **Anaphylaxis/hypersensitivity**


#### **Investigations and Treatment**

■ IgA levels: 26 (all NAD)

Bact screening unit: 20

Bact screening pt: 30

Bact screening both product and patient: 17





#### **Background**

- 12 yr old male pt with a diagnosis of Ewings Sarcoma admitted with febrile neutropenia.
- Plt count: 16 and received 1 unit of apheresis platelets

15 mins into transfusion pt developed:

- Temp rise  $36.5^{\circ}_{c}$   $38.3^{\circ}_{c}$
- Urticaria to face and neck
- Tachycardia 92 149 bpm
- Rigors
- Resp rate increased to 28 from 22, Falling O2 sats and wheeze



## Case Study - AA

#### **Investigations**

- IgA Levels: 0.8g/l
- Chest Xray NAD
- Bilateral wheeze identified on auscultation of chest

#### Intervention

- Transfusion stopped
- Pt treated with O2, Antihistamines, Anti-Pyretics, Steroids, Adrenaline nebuliser

#### **Clinical Outcome:**

Major Sequelae

## Future Requirements for this pt:

Pooled Platelets



## **Key Messages**

- Assessment of signs and symptoms when a reaction occurs is critical in the provision of treatment. Education in relation to this is fundamental
- For febrile reactions paracetamol is key treatment
- If anaphylaxis is suspected adrenaline should be available
- Steroids may take several hours to have an affect
- The common cocktail of paracetamol, steroids and antihistamines should be avoided
- Pooled platelets in PAS/HLA matched platelets should be considered with patients with recurring reactions



#### **Definition**

 Unclassified SAR is the occurrence of an adverse symptom / sign with no risk factor other than the transfusion and which on its own does not allow the reaction to be classified within the defined categories of SAR.

#### **Findings**

 Reports of 12 unclassified reactions were received which is an increase on previous reporting years.

#### Commentary

 Reporting establishments are advised to continue reporting cases with unusual symptoms or those reactions which may not fit into the criteria already in place

# Mandatory Unclassified Serious Adverse Reactions 2019-2020 (n=12)

|         | Component<br>Transfused | Age Profile                  | Imputability       | Description  |
|---------|-------------------------|------------------------------|--------------------|--|
| Case 1  | Platelets Apheresis     | Adult (51 - 70<br>years)     | Likely / Probable  | Nausea, Back Pain, Chills/Rigors, Sub sternal Discomfort                                     |
| Case i  | r tatetets Aprieresis   | Adult (51 - 70               | Likety / 1 Tobable | Dyspnoea, ↓ O2 Sats, GI Symptoms, Sub sternal  |
| Case 2  | Red Cells               | years)                       | Possible           | Discomfort   |
| Case 3  | Red Cells               | Adolescent (12-<br>17 years) | Likely / Probable  | Tingling sensation in both arms and legs, 1 hr later severe pain both legs and ankles        |
| Case 4  | Red Cells               | Adult (31-50<br>years)       | Possible           | Nausea/Vomiting, Sub sternal Discomfort, Hypotension, Tachycardia, Patient profoundly unwell |
| Ca36 4  | ned Cells               | Adult (31-50                 | 1 0331016          |  |
| Case 5  | Red Cells               | years)                       | Likely / Probable  | Tachycardia  |
| Case 6  | Red Cells               | Adult (51 - 70<br>years)     | Likely / Probable  | Hypertension, Anxiety, Dyspnoea, Chills/Rigors   |
| Case 7  | Red Cells               | Elderly (70+)                | Likely / Probable  | Cyanosis, ↓ O2 Sats, Tachycardia, Restlessness,<br>Back pain, Chills/Rigors                  |
|         | Red Cells, Platelet     | Adult (51 - 70               |                    |  |
| Case 8  | Apheresis               | years)                       | Possible           | DCT Positive, Anti A present, Falling Hb   |
| Case 9  | Red Cells               | Elderly (70+)                | Possible           | Joint Pains  |
|         |                         | Adult (18-30                 |                    |  |
| Case 10 | Red Cells               | years)                       | Likely / Probable  | Nausea, Vasovagal episode, Tachycardia   |
|         |                         | Adult (31-50                 |                    | Dyspnoea, Chest/Abdominal Pain, Back Pain,   |
| Case 11 | Platelets Apheresis     | years)                       | Possible           | Chills/Rigors  |
| Case 12 | Platelets Pooled        | Elderly (70+)                | Likely / Probable  | Dyspnoea, Back pain, Hypertension  |

|      |             |        |               |                      |          | Timeframe for | Reaction  |
|------|-------------|--------|---------------|----------------------|----------|---------------|-----------|
| Case |             | Gende  |               | Antibody             |          | developing    | caused by |
| No.  | Age         | r      | Findings      | identified           | Outcome  | antibody      | error     |
|      | Adult (51 - |        | √HB           |                      |          |               |           |
| 1    | 70 years)   | Male   | + DAT         | Anti Jk <sup>a</sup> | Death *  | 8 Days        | No        |
|      |             |        |               |                      |          |               |           |
|      | Adult (51   |        | ↑LDH,         |                      | Complete |               |           |
| 2    | - 70 years) | Female | ↑Bilirubin    | Anti Fy <sup>a</sup> | Recovery | 6 Days        | No        |
|      | Adult (51 - |        |               |                      | Complete |               |           |
| 3    | 70 years)   | Female | √Haptoglobins | Anti Jk <sup>a</sup> | Recovery | 9 Days        | No        |
|      | Adult (51 - |        | +DAT,         | Anti C               | Complete |               |           |
| 4    | 70 years)   | Male   | ↑Bilirubin    | Anti e               | Recovery | 7 Days        | No        |
|      |             |        |               | Anti c               |          |               |           |
|      | Adult (51 - |        | √Hb,          | Anti E               | Complete |               |           |
| 5    | 70 years)   | Male   | √Haptoglobins | Anti Jk <sup>a</sup> | Recovery | 9 Days        | No        |
|      |             |        | √Haptoglobins |                      |          |               |           |
|      | Adult (51 - |        | ↑LDH,         |                      | Complete |               |           |
| 6    | 70 years)   | Female | +DAT          | Anti Jk <sup>a</sup> | Recovery | 20 Days       | No        |
|      |             |        | ↑LDH          |                      |          |               |           |
|      | Adult (51 - |        | ↑Bilirubin    |                      | Complete |               |           |
| 7    | 70 years)   | Male   | √Hb           | Anti Jka             | Recovery | 8 Days        | No        |
|      |             |        | ↑Bilirubin    |                      |          |               |           |
|      | Elderly     |        | √Hb,          |                      | Complete |               |           |
| 8    | 70+ years   | Female | +DAT          | Anti E               | Recovery | 21 Days       | No        |

#### \*Death unrelated to transfusion



## **Delayed Transfusion Reactions**

Most commonly implicated antibody = Anti Jk<sup>a</sup>

#### Recommendations

- ➤ Lifesaving transfusion should not be withheld due to a history of alloantibodies.
- ➤ Robust methods of recording patients antibody history should be developed and supported with patient education



## rranstusion Transmitted Infection (n=1)

|          |      | Serious                     |                |        |              |           |           |           |
|----------|------|-----------------------------|----------------|--------|--------------|-----------|-----------|-----------|
|          |      | Adverse                     |                |        |              |           | Platelets | Platelets |
|          | Year | Reaction                    | Age            | Gender | Imputability | Red Cells | Apheresis | Pooled    |
|          |      |                             |                |        |              |           |           |           |
|          |      |                             |                |        |              |           |           |           |
|          |      | Transfusion                 | Adult (51 - 70 |        |              |           |           |           |
| 1        | 2010 | transmitted viral           | years)         | Male   | Excluded     |           |           | Yes       |
| <b>_</b> | 2013 | infection (HCV) Transfusion | ycars          | rate   | LXCIUUCU     |           |           | 103       |
|          |      | transmitted                 |                |        | Possibl      |           |           |           |
|          |      | viral infection -           | Adult (31-50   |        | 1 000150     |           |           |           |
| 2        | 2019 | Other                       | years)         | Male   | е            | Yes       |           |           |
|          |      | Transfusion                 |                |        |              |           |           |           |
|          |      | transmitted                 |                |        |              |           |           |           |
|          |      | viral infection             | Adult (51 - 70 |        |              |           |           |           |
| 3        | 2019 | (HCV)                       | years)         | Male   | Excluded     | Yes       |           |           |
|          |      | Transfusion                 |                |        |              |           |           |           |
|          |      | transmitted                 | A 1 1: (04 50  |        |              |           |           |           |
| 4        | 2010 | viral infection             | Adult (31-50   | Famala | Evaluda d    | Voo       |           |           |
| 4        | 2019 | (HCV)<br>Transfusion        | years)         | Female | Excluded     | Yes       |           |           |
|          |      | transmitted                 |                |        |              |           |           |           |
|          |      | viral infection             | Adult (51 - 70 |        | Likely /     |           |           |           |
| 5        | 2020 | (HBV)                       | years)         | Male   | Probable     | Yes       |           |           |
|          |      | Transfusion                 |                |        |              |           |           |           |
|          |      | transmitted                 |                |        |              |           |           |           |
|          |      | viral infection             | Adult (51 - 70 |        |              |           |           |           |
| 6        | 2020 | (HBV)                       | years)         | Female | Possible     | Yes       | Yes       |           |



#### **Background**

- ➤ 1995: Diagnosed Type 1 Diabetic
- ≥2014: Pt having routine haemodialysis
- ➤ Nov 2017: Received a simultaneous pancreas kidney transplant. Also received 12 units RCC
- ➤ March 2018: First identified as having Parvovirus as part of investigation of neutropenia
- ➤ May 2019: investigated for atypical parvovirus B19
- ➤ Archive samples from time of transplant tested and a high B19 was detected (14 days post transplant)



- NHO notified July 2019
- QC Dept. in IBTS aware and HPRA informed
- Transfusion Transmitted Parvovirus was posed as a potential route of transmission
- IBTS do not screen the blood supply for Parvovirus DNA or antibody
- No regulatory or legal requirement for the IBTS to provide Parvovirus screened blood
- Both the NHO and IBTS take any reports of Transfusion Transmitted Infection very seriously, an investigation was carried out



#### Investigations:

- Relevant archived samples were referred to the NVRL for Parvovirus DNA PCR and Public Health England for genotyping
- 12 implicated donors

#### Results

➤One of implicated donors had a reactive parvovirus DNA result



#### **Outcome**

 Overall the blood donation could not be excluded, the NHO accepted this case with an imputability of possible


#### **Further considerations:**

- Further review form the organ donation perspective
- Parvovirus is transmitted most commonly via droplet. The possibility of direct person to person transmission should be out ruled

### **STTI Recommendations**


- Inform NHO, IBTS Quality Department, IBTS Consultant on call or Medical Scientist on call ASAP in cases of STTI to protect the blood supply
- Where a recall involves blood components which have been transfused, hospitals should have a robust system in place which should include a review of the patient.

## **Clinical Features TACO**





## Interventions





## TACO Case Study

- 76 yr old pt with history of COPD (acutely unwell), Cardiomyopathy, htn, Recent RTI
- Hb 6.8g/dl pre transfusion
- Pt prescribed RCC X 2
- First unit transfused in the afternoon over 4 hours and second later that evening
- Pre transfusion obs prior to second unit: HR: 80bpm, BP:162/73mmHg

## Symptoms (15 mins into 2<sup>nd</sup> transfusion)

- Hypertension 162/73 180/114
- Tachycardia 80 129bpm
- Dyspnoea
- O2 sats 96% 88%
- Metabolic acidosis
- Chest Xray changes



## **TACO Case Study**

- Transfusion stopped
- Patient became very unwell and unresponsive
- Positive Fluid Balance
- Diuretics administered with effect
- O2 and nebs also used
- Sadly pt passes away following day

NHO queried as to why this already unwell patient with multiple co-morbidities was transfused RCC x 2

Questions: Was the Hb correct!

Perhaps a dilute sample

Was Hb checked following first unit

Was the second unit appropriate



## **TACO Case Study**

#### Feedback

- Possible samples were diluted no proof
- Patients clinical condition combined with low Hb result rationale for transfusion
- Agreed that a follow up Hb post first unit should have occurred

# Transfusion Associated circulatory Overload (TACO)

- 52/59 patients transfused with a reason of transfusion categorised as anaemia (WHO defined Chronic anaemia as lower than 7-8g/dL in adults)
- 45 patients developed TACO following 1 component transfused
- 11 patients developed TACO following transfusion of 2 components
- 1 patient developed TACO following transfusion of 3 components
- 1 patient developed TACO following transfusion of 4 components (Massive Haemorrhage)



### IACO as a result of an error

5 out of the total 59 accepted TACO cases reported occurred as a result of an error with **Human Failure** been identified as the cause of error

| Cas | е   |           |              |         | Syste   |                                       |
|-----|-----|-----------|--------------|---------|---------|---------------------------------------|
| Nun | nbe |           |              | Human   | m       |                                       |
| r   |     | Age       | Imputability | Failure | Failure | Error Cause                           |
|     |     | Adult     |              |         |         | Second unit prescribed and            |
|     |     | (18-30    | Likely /     |         |         | transfused in error - Lack of         |
|     | 1   | years)    | Probable     | Yes     | Yes     | Knowledge                             |
|     |     | Elderly   |              |         |         | Patient with pre-existing cardiac     |
|     | 2   | (70+)     | Possible     | Yes     |         | problems, unit transfused too quickly |
|     |     | Adult (51 |              |         |         |                                       |
|     |     | - 70      | Likely /     |         |         | 3 units prescribed, 4 units           |
|     | 3   | years)    | Probable     | Yes     |         | administered - SAH                    |
|     |     | Adult     |              |         |         |                                       |
|     |     | (18-30    | Likely /     |         |         | 2 units of RCC transfused in a short  |
|     | 4   | years)    | Probable     | Yes     | Yes     | period of time                        |
|     |     |           |              |         |         | Patient with CCF, SOB, Pitting        |
|     |     | Elderly   |              |         |         | Oedema and prescribed 2 units RCC     |
|     | Г   | (701)     | Daggibla     | Vaa     |         | avar 2. 4 haura                       |

## **TACO Checklist**

|               | Patient Risk Assessment   | Yes | No |
|---------------|---|-----|----|
| Cardiac       | Does the patient have any pre-existing co-morbidities i.e. Cardiac Failure, Hypertension, Severe aortic stenosism or moderate or severe left ventricular dysfunction? |     |    |
|               | Is this patient on regular Diuretics?  Does the patient have severe anaemia?  |     |    |
| Pulmonary     | Is the patient known to have Pulmonary Oedema  Has the patient respiratory symptoms   |     |    |
| Fluid Therapy | Is the pre-transfusion fluid balance positive? What other fluids is the patient receiving   |     |    |
|               | Is there peripheral oedema present:  Does the patient have significant renal impairment?  |     |    |

#### If any of the above risks have been identified PLEASE:

|  | Yes | No |
|--|-----|----|
| Review the patients need for Transfusion |     |    |
| Can the transfusion be safely deferred   |     |    |

### **TACO Checklist**

## If Proceeding with the transfusion please ensure the following steps are completed:

- Body Weight of patient and correct component dosing
- Transfuse a single unit of RCC and review
- Monitor Fluid Balance
- ols prophylactic Diuretics required?
- Monitor observations closely

## Mortality and morbidity data by category 2019-2020

|  | Death<br>(unrelated to<br>transfusion) | Death<br>probabl<br>y related | Death<br>possibly<br>related | Major<br>Sequlae | Minor<br>Sequla<br>e | Complet<br>e<br>Recovery | Unknown |
|--|--|-------------------------------|------------------------------|------------------|----------------------|--------------------------|---------|
| Anaphylaxis/hypersensitivity (AA)                                      |  |                               |                              | 1                | 6                    | 54                       |         |
| Immunological haemolysis due to other allo-antibody (Acute < 24 hrs)   |  |                               |                              |                  | 1                    | 1                        |         |
| Immunological haemolysis due to other allo-antibody (Delayed > 24 hrs) | 1                                      |                               |                              |                  |                      | 7                        |         |
| Hypotensive Transfusion Reaction                                       |  |                               |                              |                  | 1                    | 2                        |         |
| OSR - Febrile Non Haemolytic Transfusion Reaction                      | 1                                      |                               |                              |                  | 7                    | 64                       |         |
| OSR - Transfusion Associated Circulatory Overload (TACO)               | 4                                      |                               | 1                            | 9                | 2                    | 43                       |         |
| OSR - Transfusion Associated  Dyspnoea                                 |  |                               |                              |                  | 1                    | 3                        |         |
| OSR - Unclassified SAR   | 1                                      |                               |                              |                  | 2                    | 9                        |         |
| Transfusion transmitted viral infection - Other                        |  |                               |                              |                  |                      |                          | 1       |
| Total  | 7                                      | 0                             | 1                            | 10               | 20                   | 183                      | 1       |



#### **Transfusion Associated Circulatory Overload TACO Checklist**

|                       | Patient Risk Assessment  | Yes | No |
|-----------------------|--|-----|----|
| Cardiac               | Does the patient have any pre-existing co-morbidities i.e. Cardiac Failure, Hypertension, Severe aortic stenosis or moderate or severe left ventricular dysfunction? |     |    |
|                       | Is this patient on regular Diuretics?  |     |    |
|                       | Does the patient have severe chronic anaemia?  |     |    |
|                       | Is the patient known to have Pulmonary Oedema?   |     |    |
| Pulmonary             | Has the patient any respiratory symptoms?  |     |    |
| Fluid                 | Is the pre-transfusion fluid balance positive?   |     |    |
| Therapy/<br>Metabolic | Is the patient receiving other fluids?   |     |    |
|                       | Does the patient have low body weight? Is there hypoalbuminaemia? Is there peripheral oedema present?  Does the patient have significant renal impairment?           |     |    |

#### If any of the above risks have been identified, PLEASE:

|   | Yes | No |
|---|-----|----|
| Review the patient's need for transfusion |     |    |
| Can the transfusion be safely deferred?   |     |    |

If proceeding with the transfusion, please ensure the following steps are completed:

- Check Body Weight of patient and correct component dosing
- Transfuse a single unit of RCC and review
- Monitor Fluid Balance
- Are prophylactic Diuretics required?
- Monitor observations including O<sub>2</sub> saturation closely

# Serious adverse reactions: 2013-2015

Joanne Scanlon
National Haemovigilance Office

## Serious Adverse Reactions (SAR) - Main findings 2013-2015

In total 1,079 SAR reports submitted to NHO with 952 reports accepted 200 Reports Mandatory (21%)

50 Reports were reclassified following submission

121 Reports Did not progress


61 reports involving paediatric patients received and 58 accepted

#### No reports accepted in relation to:

- Suspected transfusion transmitted infection (bacterial)
- Transfusion Associated Graft versus Host Disease (TAvGHD),

| Serious Adverse Reactions accepted by the NHO |   |     | 2014 | 2015 |
|---|---|-----|------|------|
| Acute Transfusion reactions                   | Immunological haemolysis due to ABO<br>Incompatibility                      | 0   | 1    | 1    |
|   | Immunological haemolysis due to other allo-<br>antibody (Acute < 24 hrs.)   | 0   | 1    | 0    |
|   | Anaphylaxis/hypersensitivity (AA)   | 37  | 35   | 41   |
|   | Febrile Non Haemolytic Transfusion Reaction                                 | 65  | 70   | 65   |
|   | Unclassified SAR  | 7   | 9    | 5    |
|   | Hypotensive Transfusion Reaction  | 2   | 3    | 0    |
| Delayed Haemolytic<br>Transfusion Reactions   | Immunological haemolysis due to other allo-<br>antibody (Delayed > 24 hrs.) | 11  | 11   | 8    |
| Delayed Serological<br>Transfusion Reaction   | Delayed Serological Transfusion Reaction                                    | 102 | 220  | 168  |
| Post transfusion purpura                      | Post transfusion purpura  | 0   | 2    | 0    |
| Transfusion Transmitted viral infection (HBV) | Transfusion Transmitted viral infection (HBV)                               | 2   | 0    | 0    |
| Respiratory Complications of transfusion      | Transfusion Associated Circulatory Overload (TACO)                          | 21  | 23   | 38   |
|   | Transfusion Associated Dyspnoea   | 1   | 0    | 2    |
|   | Transfusion related acute lung injury (TRALI)                               | 0   | 1    | 0    |
| Totals  |   | 248 | 376  | 328  |
|   | Subject to change   |     |      |      |

# Age groups involved in Reportable SAR's 2013-2015



# Immunological Haemolysis due to ABO Incompatability

### Findings:

Two reports have been accepted between 2013-2015, both with an imputability of 'Certain'.

# Immunological Haemolysis due to ABO Incompatability n=2 Case Study

### **Background**

 Elderly patient with a haemoglobin of 7.4g/dl required a transfusion

### **Symptoms**

- Temperature rise within 90 mins
- Hypotension
- Haematuria new onset

### **Treatment**

Transfusion stopped

### On investigation

- Incorrect unit had been administered (O+ pt. received A+ unit)
- DAT: Negative
- Bilirubin: ↑from 17umol/L to 44 umol/L within 4 hours after transfusion
- Abnormal Renal function
- LFT's back to normal 2 days post transfusion
- LDH, Haptoglobins not done

# **Case Study**

### **Clinical Outcome:**

 Patient required dialysis for 4 weeks and ICU admission as a result of this reaction

### **Error Details**

- 2 Female patients with same name, same month and year of birth
- Both pts had blood in Issue fridge
- Incorrect unit collected by hospital porter failure to verify
- Compatability label and unit not checked against pts ID band by 2 nurses – failure to verify, failure to adhere to policies and procedures

## **Corrective Action**

- Re-education and re-training of staff involved
- Introduction of a new label for patients with same /similar names
- The Blood Track electronic scanning system is being introduced to improve safety during the *Pre-transfusion Checking Procedure(Phase 3)*

### Recommendation

Initial treatment of Acute Transfusion Reaction is not dependent on classification but should be directed by symptoms and signs. Treatment of severe reactions should not be delayed until the results of investigations are available (BCSH 2012)

There is no substitute for <u>Correct Patient Identification</u> at all stages in the transfusion process (Key SHOT message 2015)

# **Acute Allergic and Anaphylactic Transfusion Reactions**

### Implicated components:

|                     | 2013 | 2014 | 2015 |
|---------------------|------|------|------|
| Red Cells           | 12   | 10   | 11   |
| Apheresis Platelets | 17   | 20   | 21   |
| Pooled Platelets    | 8    | 3    | 6    |
| LG Octaplas         | n/a  | 2    | 1    |
| Multiple            | n/a  | n/a  | 2    |
| Total               | 37   | 35   | 41   |

# AA Reaction – Case Study

### Reaction due to IgA deficiency

- Elderly male patient group A RhD Positive transfused with one unit of RCC following orthopaedic surgery. His antibody screen was negative pre transfusion
- Approx. 10 mls of the unit had transfused when the patient developed a temperature rise, lower back pain, vomiting and dyspnoea.

### **Treatment**

The transfusion was stopped. The patient was treated with an antipyretic, antihistamines, steroids and IV fluids.

# AA Reaction – Case Study

### On investigation:

- IgA levels was less than 0.07g/l
- Bacterial investigation of patient and pack no bacterial infection after 6 days
- Serological investigations were negative.

### **Clinical Outcome**

Complete recovery

### Comment

This case was originally reported as a FNHTR but due to the IgA deficiency in the patient it was re-categorized as an AA reaction.

# **AA Reaction – Case Study Points to note**

- Irish donors are not tested for IgA deficiency
- IBTS supply washed red cells and platelets, which have reduced IgA levels
- In this case red cells from an IgA deficient donor were imported from the UK and transfused following further reactions with washed red cells

## Recommendations

### Recommendation (BCSH 2012)

For patients with recurrent moderate or severe allergic reactions, other than those in which the patient is IgA deficient, options for further transfusion include:

- > Use of directly monitored transfusion of standard components in a clinical area with resuscitation facilities
- >Anaphylaxis should be treated with intramuscular adrenaline
- >Transfusion of washed red cells or platelets
- Consider antihistamine prophylaxis (although the evidence for efficacy is low, the risks are also low)

# Febrile Non-Haemolytic Transfusion Reactions(FNHTR) n = 216

#### **Findings**

- > 216 reports received
- 200 accepted (13 mandatory)

#### **Patients:**

- Neonatal (1-12 months) 1
- ➤ Infant (1-4 years) 4
- > Child (5-11 years) 4
- Adolescent (12-17 years) -2
- > Adult (18-30 years) -14
- > Adult (31-50 years) 35
- > Adult (51 -70 years) 62
- Elderly (70+) -78

#### **Components Implicated**

- > 181 red cells
- > 19 apheresis platelets

#### **Investigations**

Majority of the cases were investigated for bacterial contamination

- > 175 patients had bacterial investigations
- ➤ 136 cases both the patient and the pack were cultured
- A further 34 cases the patient only was cultured
- 5 remaining cases only the pack was cultured

#### Clinical Outcome

- 185 Cases : Complete Recovery
- 13 Cases: Minor Sequelae (majority due to admission required from day ward)
- 2 Cases :Death as a clinical outcome, however both were unrelated to transfusion

# **BCSH Guidelines 2012**

### Recommendation

➤ Patients with recurrent febrile reactions, recommend a trial of premedication with oral paracetamol given one hour before the reaction is anticipated (or nonsteroidal anti-inflammatory drugs in patients with predominant chills or rigors - but an assessment of the risks of medication against the severity of reaction should be made in each case)

## Transfusion Associated Circulatory Overload 2013-2015

### **Findings**

- > 89 Reports received and 82 accepted
- > 10 (11%) reports fulfilled the criteria for Mandatory TACO
- > 9 reactions as a result of errors at risk patients, inappropriate transfusions

#### **Patients**

- > 57 elderly (>70 years)
- > 17 adults (51-70 years)
- > 5 adults (31-50 years)
- > 2 adult (18-30 years)
- > 1 infant (1-12 months)

### **Implicated Components**

- > 78 RCC
- ➢ 6 Apheresis platelets
- > 1 Pooled Platelets
- ➤ 2 LG Octaplas

#### **Clinical Outcome**

- > 59 (69%) made a Complete recovery
- > 11 Reports of Minor Sequelae
- > 3 Reports resulted in Major Sequelae (ventilated)
- > 9 Reports resulted in death, all of which were unrelated to transfusion

# Reporting TACO to the NHO

### NHO collect

Reports of TACO where patients exhibit clinical signs and symptoms of overload following transfusion and which do not meet the very strict criteria of the ISBT definition either in terms of the time line or evidence of four characteristics.

# Proposed ISBT revised definition TACO

# **Current Mandatory Definition(any 4 of the following)**

- Acute Respiratory distress
- Tachycardia
- Hypertension
- Pulmonary oedema
- Positive Fluid Balance

# Draft ISBT (ISBT, 2014) Primary features

- Pulmonary oedema
- Enlarged cardiac silhouette (on Cxray)
- Evidence of fluid overload

### Features to support diagnosis:

- Elevated BNP
- Increase in mean arterial pressure or increased pulmonary wedge pressure

## Rationale for the revision

At the Amsterdam(2014) meeting of the haemovigilance working party(ISBT & IHN), a number of members requested revision of the TACO definition.

Notably, strict application of the revised definition may lead to non-acceptance of cases and a decrease in nonmandatory reports which would be accepted as TACO by clinicians and by some haemovigilance systems.

### NOTE

Mandatory Definition of TACO remains unchanged (ISBT 2011)

# TACO – Paediatric Patients n=1 Case history

### **Background**

- Infant recently diagnosed with a haematological condition required an invasive procedure
- > Platelet count 22 x 109
- Transfused with one unit of apheresis platelets

#### Baseline obs

Temp: 36.2, P152, BP 087/46

### 30 mins later - (220mls transfused)

- ➤ Hypertension BP 119/43,
- ➤ Tachycardia 174,
- Dyspnoea,
- $\triangleright$  falling  $O_2$  sats

#### **Treatment:**

Commenced on CPAP, and treated with diuretics

#### On review:

- Weight 7kgs
- Transfused 33mls/kgs (10-20mls per Kg)
- Positive fluid balance > 250mls

#### Comment

Incorrect volume prescribed and transfused

## TACO - Paediatric Patients (case history)

### **Error Causes**

- > NCHD prescribed the platelets without noting patients weight
- ➤ RGN presumed this was the correct amount even though hesitated before commencing the transfusion thinking it was too much but went ahead as consultant wanted a good rise in platelet count

### **Corrective/Preventative action**


➤ Re-education and change in procedure – only a member of patients direct medical/oncology team could prescribe or cancel components.

### **Clinical Outcome**

Initially required CPAP but made a full recovery.

# **SHOT Recommendation (2015)**

A formal pre-transfusion Risk assessment for Transfusionassociated circulatory overload (TACO) should be performed wherever possible as TACO is the most commonly reported cause of death and major morbidity



# Post Transfusion Purpura n=2, Case Study

### **Treatment**

Patient was treated with HPA 1a Negative products, IVIG, Plasma exchange and Rituximab

### **Investigations**

Serological investigations resulting in identification of HLA antibodies, Anti HPA 1a identified and other platelet specific alloantibody identified

### **Outcome**

- ➤ Major Sequelae
- This patient had thrombocytopenia due to underlying condition so therefore complete recovery was impossible
- ➤ However, 1 week post reaction patient had no acute bleeding or no new subcutaneous or mucosal bleed

# **Suspected Transfusion Transmitted Infections** (n=2)

### **Findings**

Between 2013-2015 the NHO have received 18 Reports of Suspected Transfusion Transmitted Infections and in all but two cases transfusion transmitted infection has been excluded or considered unlikely as a result of investigations carried out by the IBTS.

In the final two cases (HBV infection) as all of the unit numbers transfused were not available (1976, 1986, 1990) transfusion transmitted infection could not be excluded and both cases were accepted by the NHO

# Delayed Serological Transfusion Reactions (DSTR's) n=490

## Why did NHO begin to accept DSTR reports?

- Following on from hospital inquiries and review of other European Haemovigilance systems, we commenced collection in Jan 2013
- Prior to this we advised hospitals to maintain local records
- Non-Mandatory reports

## Findings:

- >2013: 102 Reports accepted (40% of total SAR's)
- >2014: 220 Reports accepted (59% of total SAR's)
- >2015: 168 Reports accepted (57% of total SAR's)

## **Issues Identified with Reporting**

- Patient history is sometimes unknown-both Transfusion and Antibody history
- Investigate history in other facilities?
- Difficult to out-rule haemolysis completely
- Time consuming

### Conclusion

 Did DSTR analysis by hospitals lead to investigation of possible DHTRs and subsequent increase in

reporting?

Not really...

| 2013   | 2014   | 2015   |
|--------|--------|--------|
| 10/102 | 11/220 | 10/168 |

## NHO Decision Jan 2016

- Following collection of DATA for 3 years, no new findings were identified
- NHO decided to follow our UK colleagues and we ceased the acceptance of reports from Jan 2016
- HPRA informed
- **Comment**: If a decision at European level is made for these reports to become mandatory, it may be necessary to report in the future

# The next twenty five years

- Personal responsibility
- Holding to account
- Shift from adverse event reporting to improvement and innovation
- Shared decision making, patient empowerment and full open disclosure
- Develop the trust relationship
- Sentinel hospitals which will be the engines for real change